🇺🇸 FDA
Pipeline program

Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Padcev 30 mg powder for concentrate for solution for infusion, Zimberelimab, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, DOMVANALIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

IMMU-132-06

Phase 2 small_molecule active

Quick answer

Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Padcev 30 mg powder for concentrate for solution for infusion, Zimberelimab, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, DOMVANALIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion for Locally Advanced/Metastatic Urothelial Cancer is a Phase 2 program (small_molecule) at Gilead Sciences International Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Gilead Sciences International Limited
Indication
Locally Advanced/Metastatic Urothelial Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials